Фармакотерапия хронической обструктивной болезни легких с позиций современных клинических рекомендаций

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/
2. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М., 2014. http://www.pulmonology.ru/publications/guide.php?clear_cache=Y
3. Roche N, Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54 (13): 1408–13.
4. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
5. Lopez A, Murray C. The global burden of disease 1990–2020. Nat Med 1998; 4: 1241–3.
6. Nakamura M, Oshima A, Fujimoto Y et al. Efficacy and tolerability of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29 (6): 1040–56.
7. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 5 (10): 255–61.
8. Авдеев С.Н. Хроническая обструктивная болезнь легких. Карманное руководство для практических врачей. М.: Атмосфера, 2010.
9. Tashkin D, Fabbri L. Long_acting beta_agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149.
10. Donohue J, Fogarty C, Lotvall J et al. Once_daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–62.
11. Kornmann O, Dahl R, Centanni S et al. Once daily indacaterol versus twice_daily salmeterol for COPD: a placebo controlled comparison. European respiratory journal 2011; 37: 273–9.
12. Kerwin et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study Eur Respir J 2012; 40: 1106–14.
13. D’Urzo et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respiratory Research 2011; 12: 156.
14. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23: 257–67.
15. Ikeda et al. Regional quantification of muscarinic acetylcholine receptors and b-adrenoceptors in human airway. Br J Pharmacol 2012; 166: 1804–14.
16. Ferguson GT, Anzueto A, Fei R et al. Effect of fluticasone propionate/salmeterol or salmeterol on COPD exacerbations. Respir Med 2008; 102: 1099–108.
17. Kardos P, Wensker M, Glaad T, Vodelmeier C. Impact of salmaterol/fluticasone propionate versus salmoterol on exacerbations in severe CORD. Am J Respir Crit Care Med 2007; 175: 144–9.
18. Сelli B, Calverley P, Anderson J, Ferguson G. The TORCH (Towards a Revolution in CORD Health) study: salmaterol/fluticasone propionate improves health status, reduces exacerbations and improves lung function over three years (abstract). Eur Respir J 2006; 28 (Suppl. 50): 34.
19. Soler-Cataluna J, Martinez-Garcia M, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31.
20. Rabe K. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53–67.
21. Calverley P, Rabe K, Goehring U et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–94.
22. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effect of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (8470): 1552–60.
23. Zheng J, Kang J, Huang S et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008 14; 371 (9629): 2013–8.
24. Wongsurakiat P, Maranetra KN, Wasi C et al. Acute respiratory illness in patients with CORD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125 (6): 2011–20.
25. Furumoto A, Ohkusa Y, Chen M et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26 (33): 4284–9.

А.А.Зайцев, А.В.Безлепко

ФГКУ Главный военный клинический госпиталь им. акад. Н.Н.Бурденко Минобороны России